COVID-19 Vaccine, Adjuvanted
Trade name: Nuvaxoid
Vaccineapproved
Approved
May 16, 2025
Clinical trial activity
16 trials · 16 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
8
Phase 3
8
Phase 4
5
Earliest trial started Jun 20, 2021 (NCT05157178)
Timeline
Indications
Approved for
Studied for
- COVID-19 · Phase 4
- COVID-19 Vaccines · Phase 3
- HIV · Phase 3
- Leukemia, Lymphocytic, Chronic, B-Cell · Phase 3
- Lung Diseases · Phase 4
- Lymphoma, Non-Hodgkin · Phase 3
- Multiple Myeloma · Phase 3
- Organ Transplantation · Phase 3
- Respiratory Tract Infections · Phase 4
- Vaccine-Preventable Diseases · Phase 4
- Vaccines · Phase 2
Mechanism of action
- SARS-CoV-2Immunity, active
SARS-CoV-2 immunity, active
Approval history
- approvedMay 16, 2025
Chemistry & pharmacology
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5095387 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07051031 | Phase 4 | Oct 1, 2025 | Oregon Health and Science University |
| NCT06291857 | Phase 3 | Oct 21, 2024 | Novavax |
| NCT06633835 | Phase 4 | Sep 20, 2024 | Novavax, University of Utah |
| NCT06065176 | Phase 4 | Nov 22, 2023 | Novavax, University of Utah, Westat |
| NCT05925127 | Phase 2/Phase 3 (Phase 3) | Oct 16, 2023 | Novavax |
| NCT05775887 | Phase 1 | May 8, 2023 | Coalition for Epidemic Preparedness Innovations, Nucleus Network Ltd, University of Queensland |
| NCT05875701 | Phase 3 | Mar 28, 2023 | Novavax |
| NCT05556720 | Phase 3 | Oct 1, 2022 | Monash University |
| NCT05468736 | Phase 2/Phase 3 (Phase 3) | Jul 22, 2022 | Novavax |
| NCT05463068 | Phase 3 | Jul 11, 2022 | Novavax |
| NCT05409261 | Phase 2 | Jun 30, 2022 | Center for Vaccine Development CVD-Mali, Government of France, Innovative clinical research network in vaccinology (I-REIVAC), Institut National de la Santé Et de la Recherche Médicale, France, University of Paris |
| NCT05372588 | Phase 3 | May 25, 2022 | Novavax |
| NCT05249816 | Phase 3 | Mar 18, 2022 | Cogna Technology Solutions LLC, Novavax, Sheikh Khalifa Medical City |
| NCT05112848 | Phase 2 | Nov 30, 2021 | Novavax |
| NCT05142488 | Phase 4 | Nov 9, 2021 | Oswaldo Cruz Foundation |
| NCT05157178 | Phase 4 | Jun 20, 2021 | Oswaldo Cruz Foundation |
Showing 16 of 16 trials
Page 1 / 1
Organizations
Research & Development (16)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Novavax | For profit | 10 | 8 | 3 | 2021 |
| Oswaldo Cruz Foundation | Academic/Hospital | 2 | 2 | 1 | 2021 |
| University of Utah | Academic/Hospital | 2 | 1 | 1 | 2023 |
| Center for Vaccine Development CVD-Mali | Academic/Hospital | 1 | 0 | 1 | 2022 |
| Coalition for Epidemic Preparedness Innovations | Academic/Hospital | 1 | 0 | 1 | 2023 |
| Cogna Technology Solutions LLC | For profit | 1 | 1 | 1 | 2022 |
| Government of France | Government | 1 | 1 | 1 | 2022 |
| Innovative clinical research network in vaccinology (I-REIVAC) | Academic/Hospital | 1 | 0 | 1 | 2022 |
| Institut National de la Santé Et de la Recherche Médicale, France | Academic/Hospital | 1 | 0 | 1 | 2022 |
| Monash University | Academic/Hospital | 1 | 1 | 1 | 2022 |
| Nucleus Network Ltd | For profit | 1 | 0 | 1 | 2023 |
| Oregon Health and Science University | Academic/Hospital | 1 | 1 | 1 | 2025 |
| Sheikh Khalifa Medical City | Academic/Hospital | 1 | 0 | 1 | 2022 |
| University of Paris | Academic/Hospital | 1 | 0 | 1 | 2022 |
| University of Queensland | Academic/Hospital | 1 | 1 | 1 | 2023 |
| Westat | For profit | 1 | 0 | 1 | 2023 |
16 organizations
Page 1 / 1